Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

0QNA

Basilea Pharmaceutica (0QNA)

Basilea Pharmaceutica Ag
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QNA
DateTimeSourceHeadlineSymbolCompany
06/20/20241:15AMUK RegulatoryBasilea verpartnert Onkologie-Wirkstoffkandidat Lisavanbulin mit Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
06/20/20241:15AMUK RegulatoryBasilea partners oncology drug candidate lisavanbulin with Glioblastoma FoundationLSE:0QNABasilea Pharmaceutica Ag
05/16/20241:15AMUK RegulatoryStrong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
05/16/20241:15AMUK RegulatoryStarke Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
05/03/20241:15AMUK RegulatoryBasilea berichtet über Präsentation neuer Daten zu Ceftobiprol (Zevtera®) auf dem Fachkongress ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
05/03/20241:15AMUK RegulatoryBasilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024LSE:0QNABasilea Pharmaceutica Ag
04/24/202412:00PMUK RegulatoryBasilea-Aktionäre genehmigen an der Generalversammlung alle Anträge des VerwaltungsratsLSE:0QNABasilea Pharmaceutica Ag
04/24/202412:00PMUK RegulatoryBasilea shareholders approve all proposals of the board of directors at the annual general meetingLSE:0QNABasilea Pharmaceutica Ag
04/09/20241:15AMUK RegulatoryBasilea erhält CARB-X-Förderung für die Entwicklung einer kürzlich erworbenen neuen Antibiotika-WirkstoffklasseLSE:0QNABasilea Pharmaceutica Ag
04/09/20241:15AMUK RegulatoryBasilea awarded CARB-X grant to develop recently acquired novel class of antibioticsLSE:0QNABasilea Pharmaceutica Ag
04/04/20241:15AMUK RegulatoryBasilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicationsLSE:0QNABasilea Pharmaceutica Ag
04/04/20241:15AMUK RegulatoryBasilea gibt Erhalt der US-FDA-Zulassung für Antibiotikum ZEVTERA® (Ceftobiprol-Medocaril) für drei Indikationen bekanntLSE:0QNABasilea Pharmaceutica Ag
03/11/20242:15AMUK RegulatoryContinued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to BasileaLSE:0QNABasilea Pharmaceutica Ag
03/11/20242:15AMUK RegulatoryAnhaltend gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen Meilensteinzahlung an Basilea ausLSE:0QNABasilea Pharmaceutica Ag
02/13/20241:15AMUK RegulatoryBasilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolioLSE:0QNABasilea Pharmaceutica Ag
02/13/20241:15AMUK RegulatoryBasilea meldet starkes Gesamtjahr 2023 mit einer über der Guidance liegenden Profitabilität trotz substanziell erweitertem F&E-PortfolioLSE:0QNABasilea Pharmaceutica Ag
 Showing the most relevant articles for your search:LSE:0QNA